Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Podcast Heart Valve Matters

Results from ACURATE IDE with Janar Sathananthan, Ole De Backer, and Michael Reardon

November 29, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

A Closer Look at the ACURATE IDE Study

Presenter: NULL

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation TCT 2024

Benefits of MR Elimination & "Why TMVR"

Presenter: Michael Reardon

October 29, 2024

Podcast TCTMD Talking Points

Four-Year Results: The EVOLUT Low Risk Trial

June 12, 2024

Presentation NY Valves 2024

Global Experience With Transapical TMVR - Does Access Impact Clinical Outcomes?

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

TAVR Will Have a Longer Lasting Durability Than SAVR

Presenter: Michael J. Reardon

June 06, 2024

Presentation NY Valves 2024

Hemodynamic Performance and Restoration of Laminar Flow

Presenter: Michael J. Reardon

June 05, 2024

Presentation NY Valves 2024

The Lifetime Management of Aortic Stenosis: A Heart Team Perspective

Presenter: Michael J. Reardon

June 05, 2024

Partner Content

A Critical Assessment of Valve Performance and Outcomes in Patients at Low Risk for Surgery

January 25, 2024

Advertisement

Results from ACURATE IDE with Janar Sathananthan, Ole De Backer, and Michael Reardon

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

A Closer Look at the ACURATE IDE Study

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Benefits of MR Elimination & "Why TMVR"

Four-Year Results: The EVOLUT Low Risk Trial

Global Experience With Transapical TMVR - Does Access Impact Clinical Outcomes?

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

TAVR Will Have a Longer Lasting Durability Than SAVR

Hemodynamic Performance and Restoration of Laminar Flow

The Lifetime Management of Aortic Stenosis: A Heart Team Perspective

A Critical Assessment of Valve Performance and Outcomes in Patients at Low Risk for Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content